Highlights

  • Sigma Healthcare (ASX:SIG) reported FY26 revenue of AUD 10.8 billion, up 15.5% on a normalised pro-forma basis.
  • FY26 normalised EBIT reached AUD 1.09 billion, while normalised NPAT was AUD 732.3 million.
  • Australian Chemist Warehouse sales increased 12.1% from 1 July to 16 October 2026.
  • The October AGM update detailed international sales growth of 30.2% for the September quarter.

Sigma Healthcare Limited operates pharmacy franchising, pharmaceutical wholesale distribution and healthcare logistics businesses, including Chemist Warehouse, Amcal and Discount Drug Stores. On 22 October 2026, Sigma Healthcare (ASX:SIG) was priced at AUD 2.75, with a reported daily change of 0.00%. Its latest operating disclosure, released for the annual general meeting on 21 October, updated trading across Australian and international Chemist Warehouse networks following the company’s FY26 annual results.

Company Business

Sigma supports community pharmacies through franchise services, product sourcing, wholesale supply and distribution. Its Australian franchised network includes Chemist Warehouse, Amcal and Discount Drug Stores, while wholesale operations deliver prescription medicines and other pharmacy products to retail customers. The business also provides contract logistics services for healthcare and related products. International retail activities span New Zealand, Ireland, Dubai and China, with development plans disclosed for additional markets.

Sigma Healthcare (ASX:SIG) reports Australian and international operations and works with pharmacies operating under distinct formats. Revenue and profits reflect a combination of distribution activities, franchise-related income and other group operations. Retail network sales reported for franchised stores are a trading measure and should not be treated as identical to consolidated group revenue.

Recent Development

At its 21 October 2026 annual general meeting, Sigma reported that Australian Chemist Warehouse branded-store sales rose 12.1% for the period from 1 July to 16 October, including 9.8% like-for-like growth. International branded-store sales increased 30.2% in constant currency for the three months ending 30 September, with like-for-like sales growth of 15.8%. These periods differ and should be read separately.

Sigma Healthcare (ASX:SIG) stated that discretionary categories including women’s fragrances, vitamins and supplements were experiencing softer demand amid cost-of-living pressures. The company separately cited trading in beauty, healthcare and GLP-1-related products. Its AGM update identified planned first-half onboarding of 14 Chemist Warehouse stores and 42 Amcal and Discount Drug Stores in Australia, alongside 19 stores internationally. The targets are management plans rather than completed openings.

During 2026, Sigma also outlined plans for a new distribution facility south of Auckland. The announced lease covers approximately 23,000 square metres and contemplated a contribution of about AUD 40 million. The company indicated an expected operational timetable in the second half of calendar 2027, subject to implementation.

Financial Performance and Sector Context

For the year ended 30 June 2026, Sigma reported revenue of AUD 10.8 billion, representing growth of 15.5% against its normalised pro-forma comparison. Normalised EBIT increased 20.6% to AUD 1,090.0 million, with a normalised EBIT margin of 10.1%. Normalised NPAT increased 22.3% to AUD 732.3 million. These growth percentages use a comparable pro-forma base rather than a simple comparison of statutory reported revenue across periods affected by the merger.

Sigma Healthcare (ASX:SIG) reported net debt of AUD 663 million at FY26 year-end and a debt-to-normalised-EBITDA ratio of 0.57 times. It also disclosed AUD 32.6 million of integration synergies delivered during FY26 against an objective of AUD 100 million annually by FY29. Australian segment revenue grew 14.9%, while international segment EBIT reached AUD 55.8 million, an increase of 91.3%.

Pharmacy trading is influenced by prescription dispensing, consumer expenditure on non-prescription goods, healthcare regulation and distribution costs. In its October update, Sigma distinguished weaker demand in certain discretionary lines from demand in other healthcare-related categories. Like-for-like sales figures help identify trading at comparable stores but do not themselves measure group profitability or cash generation.

Risks to Consider

Key execution considerations include completing store onboarding, maintaining pharmaceutical distribution service levels and integrating systems across the combined group. Changes in consumer spending, medicine reimbursement arrangements, labour costs and warehouse implementation timetables could affect operating outcomes. International expansion also introduces currency, regulatory and local operating requirements. Sigma Healthcare (ASX:SIG) must manage these factors while pursuing its disclosed synergy objectives.

What to Watch Next

The next monitoring points include the remainder of first-half FY27 Chemist Warehouse trading, completion of the planned store additions and changes in like-for-like sales trends. Investors can also track progress on integration savings, net debt, international expansion and the Auckland distribution project. Formal half-year results will provide a fuller view of whether retail network trading translates into consolidated revenue, margins and cash flow.

Key Insights

Sigma Healthcare (ASX:SIG) entered FY27 after reporting increased FY26 normalised earnings and a decline in net debt. Its October trading update recorded sales growth across domestic and international Chemist Warehouse stores while identifying softness in selected discretionary categories. Financial reporting, store openings, integration execution and distribution investment remain the principal measurable developments to monitor.